VIVOS THERAPEUTICS, INC. Financials Vivos Therapeutics, Inc.
Equities
VVOS
US92859E2072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.59 USD | 0.00% |
|
-1.89% | -79.18% |
| Apr. 01 | Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures | MT |
| Apr. 01 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 104.4 | 51.78 | 9.251 | 14.89 | 7.724 | - |
| Enterprise Value (EV) 1 | 104.4 | 51.78 | 9.251 | 14.89 | 7.724 | 7.724 |
| P/E ratio | -4.22 x | -2.34 x | -0.39 x | -1.12 x | -0.66 x | -1.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 7.99 x | 3.07 x | 0.58 x | 1.08 x | 0.48 x | 0.4 x |
| EV / Revenue | 7.99 x | 3.07 x | 0.58 x | 1.08 x | 0.48 x | 0.4 x |
| EV / EBITDA | - | - | -379,725 x | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 6.36 x | - | - | - | -1.12 x | -0.48 x |
| Nbr of stocks (in thousands) | 707 | 920 | 920 | 1,197 | 2,982 | - |
| Reference price 2 | 147.8 | 56.25 | 10.05 | 12.44 | 2.590 | 2.590 |
| Announcement Date | 3/25/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 13.07 | 16.88 | 16.02 | 13.8 | 16.1 | 19.11 |
| EBITDA | - | - | -24.36 | - | - | - |
| EBIT 1 | -8.709 | -20.38 | -25.03 | -17.3 | -10.7 | -10.16 |
| Operating Margin | -66.65% | -120.71% | -156.21% | -125.32% | -66.46% | -53.17% |
| Earnings before Tax (EBT) 1 | -12.06 | -20.29 | -23.84 | -13.58 | -10.7 | -10.18 |
| Net income 1 | -17.99 | -20.29 | -23.84 | -13.58 | -10.7 | -10.18 |
| Net margin | -137.67% | -120.15% | -148.81% | -98.42% | -66.46% | -53.3% |
| EPS 2 | -35.00 | -24.00 | -26.00 | -11.14 | -3.950 | -2.285 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/25/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.546 | 4.394 | 3.46 | 4.246 | 3.95 | 3.857 | 3.395 | 3.301 | 3.248 | 3.5 | 3.8 | 4.3 | 4.5 | 4.1 |
| EBITDA | - | - | - | - | -5.894 | - | -4.369 | -3.339 | - | - | - | - | - | - |
| EBIT 1 | -5.503 | -7.411 | -6.823 | -5.407 | -6.063 | -5.005 | -4.517 | -3.489 | -4.284 | -3.1 | -2.8 | -2.4 | -2.3 | -2.5 |
| Operating Margin | -121.04% | -168.65% | -197.2% | -127.34% | -153.49% | -129.76% | -133.05% | -105.7% | -131.9% | -88.57% | -73.68% | -55.81% | -51.11% | -60.98% |
| Earnings before Tax (EBT) 1 | -5.453 | -7.393 | -5.515 | -5.434 | -6.089 | -1.703 | -5.528 | -2.093 | -4.259 | -3.1 | -2.8 | -2.4 | -2.3 | -2.5 |
| Net income 1 | -5.453 | -7.393 | -5.515 | -5.434 | -6.089 | -1.703 | -5.528 | -2.093 | -4.259 | -3.1 | -2.8 | -2.4 | -2.3 | -2.5 |
| Net margin | -119.96% | -168.24% | -159.39% | -127.98% | -154.15% | -44.15% | -162.83% | -63.41% | -131.13% | -88.57% | -73.68% | -55.81% | -51.11% | -60.98% |
| EPS 2 | -6.500 | -8.500 | -6.500 | -6.500 | -5.000 | -1.750 | -4.500 | -1.750 | -3.050 | -1.160 | -1.050 | -0.8900 | -0.8500 | -0.9200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 12/20/22 | 3/30/23 | 6/8/23 | 8/16/23 | 11/14/23 | 3/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -257% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -109% | - | - | - | - | - |
| Assets 1 | 16.44 | - | - | - | - | - |
| Book Value Per Share 2 | 23.20 | - | - | - | -2.310 | -5.390 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | 0.12 | - | 0.92 | - | 0.7 | 0.7 |
| Capex / Sales | 0.92% | - | 5.77% | - | 4.35% | 3.66% |
| Announcement Date | 3/25/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.59
USD
Average target price
7.225
USD
Spread / Average Target
+178.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -79.18% | 7.72M | |
| +72.92% | 12.36B | |
| -19.68% | 7.83B | |
| +16.20% | 7.21B | |
| +5.39% | 5.97B | |
| +7.49% | 5.14B | |
| +23.97% | 4.43B | |
| -18.81% | 3.9B | |
| -41.54% | 2.2B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- VVOS Stock
- Financials Vivos Therapeutics, Inc.
